Epigenetics Market to Reach Valuation of USD 3.0 Billion by 2028 - Increasing Technological Advancements in the Healthcare Sector is Driving the Market

In terms of revenue, the Global Epigenetics Market is expected to reach USD 3.0 Billion by 2028, growing at a Compound Annual Growth Rate (CAGR) of 13.1% from 2022 to 2028. Increasing technology in the healthcare sector along with utilizing advanced solutions for gene therapy and speeding up recuperation are the driving factors for Epigenetics Market.

Key Findings:

• Under the product segment, the kits & assays sub-segment is anticipated to dominate the growth for Epigenetics Market at a substantial Compound Annual Growth Rate (CAGR), owing to the sheer use, need throughout the protocol, and additional pre-requisite steps of DNA study.
• The oncology sub-segment held a market significant share in 2021. This is the fastest-growing segment in Epigenetics Market because of the large expenditure on healthcare research, and the availability of a wide range of medical products and thus, fueling the market growth.
• North America is the largest regional segment. This is due to its increase in the use of Epigenetics and extraordinary Research and Development (R&D) facility provided by the key market players.

Some of key players in Epigenetics Market include - Illumina (US), Thermo Fisher Scientific (US), Merck Millipore (US), Abcam (UK), Active Motif (US), Bio-Rad Laboratories (US), New England Biolabs (US), Agilent (US), QIAGEN (Netherlands), Zymo Research (US), PerkinElmer (US), and Diagenode (Belgium) are the major companies operating in Epigenetics Market..

According to the WHO, almost 70% of casualties from cancer happen in low- and middle-income nations, and only one in five has the required data to drive cancer-related guidelines. This worldwide threat of cancer stays as a major driver for the expansion of new cancer therapies which in turn, helps in the examination, earlier diagnosis, and adequate monitoring of the therapy.

Moreover, the benefit of targeted antiviral treatments such as rapamycin, ribavirin, and other epigenetic drugs like BRD4 inhibitors, DNMT1 inhibitors, & HDAC inhibitors have been shown to mainly inhibit the virus operation. Researchers have begun to comprehend how Epigenetics may prevent viral proliferation so that vaccines & therapeutics can be created to specifically target replicating mechanisms of a virus. Therefore, the rise in the number of epigenetic researches and growth in cognition of epigenetic drugs for the treatment of coronavirus infection is expected to show an overall favorable impact on the Epigenetics industry.

North America is expected to emerge as the largest market growth in 2021. This is attributed to the fast developments in healthcare infrastructure, the existence of major players in the region, and massive investments made in Research and Development (R&D). Growing investments being made in the Research and Development (R&D) products by enterprises and increasing need for protein expression techniques are anticipated, as many mammalian proteins, such as growth hormone, insulin, antibodies, and vaccines, are produced by industries.